Heart Diseases Clinical Trials in Los Angeles, California

6 studies are recruiting for heart diseases in Los Angeles, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

   The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.

   Stage

   Not phased

   Ages

   18 to 100

   Site

   Cedars-Sinai Medical Center, Los Angeles, California

   Locations

   47 in total

   Run by

   BrioHealth Solutions, Inc.

   See if you can join NCT06310031 on ClinicalTrials.gov

2. Abbott Structural Heart Device Registry

   The Abbott Structural Heart (SH) Registry is being conducted to confirm the safety and performance of Abbott's SH devices in a post-market, real-world setting. The Registry primarily involves gathering data from routine hospital practices and standard-of-care (SOC) procedures administered to patien…

   Stage

   Not phased

   Ages

   Any age

   Site

   USC University Hospital, Los Angeles, California

   Locations

   36 in total

   Run by

   Abbott Medical Devices

   See if you can join NCT06590467 on ClinicalTrials.gov

3. Transition to KPL-387 Monotherapy Dosing & Administration Study

   The primary objective of this study is to characterize the efficacy and safety of dosing regimens used to transition from prior pericarditis therapies to KPL-387 monotherapy in participants with well-controlled recurrent pericarditis on standard therapies.

   Stage

   Phase 2

   Ages

   18 to 80

   Site

   Investigational Site 014, Los Angeles, California

   Locations

   41 in total

   Run by

   Kiniksa Pharmaceuticals International, plc

   See if you can join NCT07288216 on ClinicalTrials.gov

4. Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

   Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall a…

   Stage

   Phase 3

   Ages

   18 to 75

   Site

   University of California, Los Angeles (UCLA) - David Geffen School of Medicine, Los Angeles, California

   Locations

   104 in total

   Run by

   Eidos Therapeutics, a BridgeBio company

   See if you can join NCT06563895 on ClinicalTrials.gov

5. The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR

   The objective of this prospective, randomized, double- blinded (patient and assessors), sham-controlled clinical trial is to assess the safety and efficacy of the CMCS in treating heart failure with functional regurgitation (FMR).

   Stage

   Not phased

   Ages

   18 and older

   Site

   Keck School of Medicine of USC, Los Angeles, California

   Locations

   92 in total

   Run by

   Cardiac Dimensions, Inc.

   See if you can join NCT03142152 on ClinicalTrials.gov

6. Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

   The central hypothesis of ROMA:Women is that the use of multiple arterial grafting (MAG) will improve clinical outcomes and quality of life (QOL) compared to single arterial grafting (SAG). The specific aims of ROMA:Women are: Aim 1: Determine the impact of MAG vs SAG on major adverse cardiac and c…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Cedars-Sinai Medical Center, Los Angeles, California

   Locations

   146 in total

   Run by

   Weill Medical College of Cornell University

   See if you can join NCT04124120 on ClinicalTrials.gov